Jefferies Sees Reduced Upside for Arbutus Biopharma Corporation (ABUS) on Higher Appeal Probability

Why It Matters

The revised valuation reflects heightened litigation risk, which could dampen investor returns and reshape funding expectations for ABUS’s hepatitis B pipeline.

Key Takeaways

• Jefferies cut ABUS price target to $5.50 from $7.00.
• Appeal win probability for Moderna increased, lowering ABUS upside.
• ABUS expects $950M upfront payment in July 2026, plus $1.3B contingent.
• Q4 2025 revenue $14.1M; net loss $33.5M; cash $91.5M.
• Cost cuts via restructuring improve operating expense profile.

Pulse Analysis

Arbutus Biopharma’s valuation is now tightly linked to the outcome of its patent dispute with Moderna. The company stands to receive an upfront $950 million payment in July 2026, with an additional $1.3 billion contingent on a favorable appellate ruling. Jefferies recently raised the probability that Moderna will prevail on appeal, a shift that compresses the upside embedded in those contingent proceeds. In biotech, litigation risk often drives wide swings in market multiples, and a higher win probability for the defendant can quickly erode expected future cash flows.

Despite the legal headwinds, Arbutus reported Q4 2025 revenue of $14.1 million and a net loss of $33.5 million, while ending the year with $91.5 million in cash and short‑term investments. The company’s recent restructuring and cost‑optimization program trimmed operating expenses, extending its cash runway into 2027 under current burn rates. For investors, the balance sheet strength provides a cushion to continue advancing its hepatitis B RNA‑interference pipeline, but the sizable loss underscores the need for near‑term commercial or partnership milestones to justify the valuation.

Jefferies kept a Buy rating on ABUS but cut its price target to $5.50, reflecting the revised upside scenario. The downgrade signals that analysts now price in a more modest upside from the contingent $1.3 billion, while still valuing the company’s core technology platform and cash position. In a broader context, the episode illustrates how biotech firms with high‑value IP disputes can see rapid sentiment shifts, prompting investors to weigh litigation risk alongside scientific progress. Future catalysts for Arbutus will likely hinge on clinical readouts and the final appellate decision.